Erratum: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the american college of cardiology/American Heart Association Task Force on Practice Guidelines (Circulation (2014) 129 (S1-S45) DOI: 10.1161/01.cir.0000437738.63853.7a);2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the american college of cardiology/american heart association task force on practice guidelines

Circulation

Volumn 129, Issue 25 SUPPL. 1, 2014, Pages e396-

  Stone, Neil J ^a   Robinson, Jennifer G ^a   Lichtenstein, Alice H ^a   Bairey Merz, C Noel ^a   Blum, Conrad B ^a   Eckel, Robert H ^a   Goldberg, Anne C ^a   Gordon, David ^a   Levy, Daniel ^a   Lloyd Jones, Donald M ^a   McBride, Patrick ^a   Schwartz, J Sanford ^a   Shero, Susan T ^a   Smith, Sidney C ^a   Watson, Karol ^a   Wilson, Peter W F ^a  

^a NONE

Author keywords

AHA Scientific Statements; biomarkers, pharmacological; cardiovascular disease; cholesterol; diabetes mellitus; drug therapy; hydroxymethylglutaryl CoA reductase inhibitors statins; hypercholesterolemia; lipids; patient compliance; primary prevention; risk assessment; risk reduction behavior; secondary prevention

Indexed keywords

AMIODARONE; ANABOLIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CHOLESTEROL; CYCLOSPORIN; DIURETIC AGENT; ESTROGEN; EZETIMIBE; FLUINDOSTATIN; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PITAVASTATIN; PRAVASTATIN; PROTEINASE INHIBITOR; RALOXIFENE; RAPAMYCIN; RETINOIC ACID; ROSUVASTATIN; SIMVASTATIN; TAMOXIFEN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ADULT; BIBLIOGRAPHIC DATABASE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FOLLOW UP; HEALTH PROMOTION; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIFESTYLE; LIFESTYLE MODIFICATION; LIPID ANALYSIS; LIPID BLOOD LEVEL; MEDICAL SOCIETY; OBESITY; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; STABLE ANGINA PECTORIS; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS;

AHA SCIENTIFIC STATEMENTS; BIOMARKERS, PHARMACOLOGICAL; CARDIOVASCULAR DISEASE; CHOLESTEROL; DIABETES MELLITUS; DRUG THERAPY; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS/STATINS; HYPERCHOLESTEROLEMIA; LIPIDS; PATIENT COMPLIANCE; PRIMARY PREVENTION; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; SECONDARY PREVENTION;

AMERICAN HEART ASSOCIATION; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; HUMANS; HYPERCHOLESTEROLEMIA; PRIMARY PREVENTION; RISK FACTORS; SECONDARY PREVENTION; UNITED STATES;

EID: 84897970506     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0000000000000346     Document Type: Erratum

References (142)

1. Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines; Graham R. Clinical Practice Guidelines We Can Trust. Washington, D.C.: National Academies Press; 2011.
2. Gibbons GH, Harold JG, Jessup M, et al. The next steps in developing clinical practice guidelines for prevention. J Am Coll Cardiol. 2013;62:1399-400.
3. Gibbons GH, Shurin SB, Mensah GA, et al. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute. Circulation. 2013;128:1713-5.
4. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart Lung and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128 (Suppl 5):S213-56.
5. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240-327.
6. National Cholesterol Education Program (US), National Heart, Lung, and Blood Institute, National Institutes of Health. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Bethesda, MD: National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health; 2002. NIH Publication No. 02-5215.
7. Grundy S, Cleeman J, Merz C, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39. (Pubitemid 38924592)
8. National Cholesterol Education Program (US) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III) Final report. Circulation. 2002;106:3143-421.
9. AIM-HIGH Investigators; Boden WE, Probstfeld JL. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;67:2255-67.
10. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S76-S99.
11. Goff DC Jr., Lloyd-Jones DM, D'Agostino RB Sr., et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49-S73.
12. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013.
13. Cholesterol Treatment Trialists' (CTT) Collaborators; Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-90.
14. ACCORD Study Group; Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-74.
15. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011:CD004816.
16. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
17. Downs JR, Clearfeld M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22. (Pubitemid 28248586)
18. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368:1155-63. (Pubitemid 44444932)
19. Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101:1689-93.
20. Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L. Effcacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.
21. Tikkanen MJ, Holme I, Cater NB, et al. Comparison of effcacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental Decrease through Aggressive Lipid Lowering [IDEAL] study). Am J Cardiol. 2009;103:577-82.
22. Holmes HM, Hayley DC, Alexander GC, et al. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166:605-9.
23. Akushevich I, Kravchenko J, Ukraintseva S, et al. Age patterns of incidence of geriatric disease in the US elderly population: Medicare-based analysis. J Am Geriatr Soc. 2012;60:323-7.
24. Wolff JL, Starfeld B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162:2269-76. (Pubitemid 35332510)
25. Fried TR, Tinetti ME, Towle V, et al. Effects of benefts and harms on older persons' willingness to take medication for primary cardiovascular prevention. Arch Intern Med. 2011;171:923-8.
26. Robinson JG, Bakris G, Torner J, et al. Is it time for a cardiovascular primary prevention trial in the elderly? Stroke. 2007;38:441-50. (Pubitemid 46184321)
27. Porock D, Oliver D, Zweig S, et al. Predicting death in the nursing home: development and validation of the 6-month Minimum Data Set mortality risk index. J Gerontol A Biol Sci Med Sci. 2005;60:491-98. (Pubitemid 40712868)
28. Stineman MG, Xie D, Pan Q, et al. All-cause 1-, 5-, and 10-year mortality in elderly people according to activities of daily living stage. J Am Geriatr Soc. 2012;60:485-92.
29. Schonberg MA, Davis RB, McCarthy EP, et al. External validation of an index to predict up to 9-year mortality of community-dwelling adults aged 65 and older. J Am Geriatr Soc. 2011;59:1444-51.
30. Fried TR, Tinetti ME, Iannone L, et al. Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions. Arch Intern Med. 2011;171:1854-56.
31. Barry MJ, Edgman-Levitan S. Shared decision making-pinnacle of patient-centered care. N Engl J Med. 2012;366:780-1.
32. Man-Son-Hing M, Gage B, Montgomery AA. Preference-based anti-thrombotic therapy in atrial fbrillation: implications for clinical decision making. Med Decis Making. 2005;25:548-59. (Pubitemid 41384068)
33. Fried TR, Bradley EH, Towle VR, et al. Understanding the treatment preferences of seriously ill patients. N Engl J Med. 2002;346:1061-6. (Pubitemid 34984621)
34. Ditto PH, Druley JA, Moore KA, et al. Fates worse than death: the role of valued life activities in health-state evaluations. Health Psychol. 1996;15:332-43. (Pubitemid 126483562)
35. Rosenfeld KE, Wenger NS, Kagawa-Singer M. End-of-life decision making: a qualitative study of elderly individuals. J Gen Intern Med. 2000;15:620-5.
36. Nease RJ, Kneeland T, O'Connor GT, et al. Variation in patient utilities for outcomes of the management of chronic stable angina: Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team. JAMA. 1995;273:1185-90.
37. Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Int Med. 2010;152:488-96. W174.
38. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-30. (Pubitemid 35379733)
39. Trompet S, van Vliet P, de Craen AJM, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol. 2010;257:85-90.
40. Gray SL, Boudreau RM, Newman AB, et al. Angiotensin-converting enzyme inhibitor and statin use and incident mobility limitation in community-dwelling older adults: the Health, Aging and Body Composition Study. J Am Geriatr Soc. 2011;59:2226-32.
41. LaCroix AZ, Gray SL, Aragaki A, et al. Statin use and incident frailty in women aged 65 years or older: prospective fndings from the Women's Health Initiative Observational Study. J Gerontol A Biol Sci Med Sci. 2008;63:369-75. (Pubitemid 351738418)
42. Hippisley-Cox J, Pringle M, Cater R, et al. Coronary heart disease prevention and age inequalities: the frst year of the National Service Framework for CHD. Br J Gen Pract. 2005;55:369-75. (Pubitemid 40585211)
43. Forman DE, Rich MW, Alexander KP, et al. Cardiac care for older adults. Time for a new paradigm. J Am Coll Cardiol. 2011;57:1801-10.
44. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2969-89.
45. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientifc statement from the American Heart Association. Circulation. 2011;123:2292-333.
46. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35. (Pubitemid 40471450)
47. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvas-tatin vs usual-dose simvastatin for secondary prevention after myocar-dial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-45. (Pubitemid 41627921)
48. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504. (Pubitemid 38477774)
49. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.
50. Baigent C, Keech A, Kearney P, et al. Effcacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
51. Thompson GR, Packard CJ, Stone NJ. Goals of statin therapy: three viewpoints. 2002. Atheroscler Suppl. 2004;5:107-14.
52. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefts and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565-71.
53. Roff M, Angiolillo DJ, Kappetein AP. Current concepts on coronary revascularization in diabetic patients. Eur Heart J. 2011;32:2748-57.
54. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-53. (Pubitemid 41817713)
55. Rhodes ET, Prosser LA, Hoerger TJ, et al. Estimated morbidity and mortality in adolescents and young adults diagnosed with Type 2 diabetes mel-litus. Diabet Med. 2012;29:453-63.
56. Paynter NP, Mazer NA, Pradhan AD, et al. Cardiovascular risk prediction in diabetic men and women using hemoglobin A1c vs diabetes as a high-risk equivalent. Arch Intern Med. 2011;171:1712-18.
57. Elley CR, Robinson E, Kenealy T, et al. Derivation and validation of a new cardiovascular risk score for people with type 2 diabetes: the New Zealand Diabetes Cohort Study. Diabetes Care. 2010;33:1347-52.
58. Stevens RJ, Coleman RL, Adler AI, et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care. 2004;27:201-7. (Pubitemid 38196733)
59. Bibbins-Domingo K, Coxson P, Pletcher MJ, et al. Adolescent overweight and future adult coronary heart disease. N Engl J Med. 2007;357:2371-79. (Pubitemid 350244535)
60. Daniels SR, Jacobson MS, McCrindle BW, et al. American Heart Association Childhood Obesity Research Summit Report. Circulation. 2009;119:e489-517.
61. Jacob M, Cho L. Asian Americans and cardiometabolic risk: why and how to study them. J Am Coll Cardiol. 2010;55:974-75.
62. Bainey KR, Jugdutt BI. Increased burden of coronary artery disease in South-Asians living in North America. Need for an aggressive management algorithm. Atherosclerosis. 2009;204:1-10.
63. Yu T, Vollenweider D, Varadhan R, et al. Support of personalized medicine through risk-stratifed treatment recommendations-an environmental scan of clinical practice guidelines. BMC Med. 2013;11:7.
64. Lescol (fuvastatin sodium) [prescribing information]. Novartis Pharmaceuticals. East Hanover, NJ; 2012.
65. Pravachol (pravastatin sodium) [prescribing information]. Bristol Myers Squibb Co. Princeton, NJ; 2012.
66. Livalo (pitivastatin) [prescribing information]. Kowa Pharmaceuticals. Montgomery AL; 2012.
67. Zocor (Simvastatin) [prescribing information]. Merck & Co. Whitehouse Station, NJ; 2012.
68. Mevacor (Lovastatin) [prescribing information]. Merck & Co. Whitehouse Station, NJ; 2012.
69. Lipitor (atorvastatin calcium) [prescribing information]. Pfzer Inc. New York, NY; 2012.
70. Crestor (rosuvastatin calcium) [prescribing information]. AstraZeneca Pharmaceuticals. Wilmington DE; 2013.
71. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-89.
72. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-7.
73. Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-9. (Pubitemid 26338729)
74. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-57.
75. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96. Deleted in press. (Pubitemid 39140624)
76. Amarenco P, Bogousslavsky J, Callahan Ar, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-59. (Pubitemid 44202151)
77. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-59.
78. Vodnala D, Rubenfre M, Brook RD. Secondary causes of dyslipidemia. Am J Cardiol. 2012;110:823-25.
79. Stone NJ, Blum CB. Management of Lipids in Clinical Practice. 7th ed. Caddo, OK: Professional Communications; 2008.
80. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735-42.
81. Guiding the guidelines. Lancet. 2011;377:1125.
82. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III). JAMA. 2001; 285: 2486-97.
83. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-407.
84. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-61. (Pubitemid 350190755)
85. Gissi-HF Investigators; Tavazzi L, Maggioni AP, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231-39.
86. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-48. (Pubitemid 41058323)
87. Eckel RH. Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab. 2010;95:2015-22.
88. US Food and Drug Administration. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs. Rockville, MD: US Food and Drug Administration; 2012.
89. US Food and Drug Administration. FDA Drug Safety Communication: ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. Rockville, MD: US Food and Drug Administration; 2010.
90. Association AD. Standards of medical care in diabetes-2013. Diabetes Care. 2013;2011;36 (Suppl 1):S11-66.
91. Rawlins M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet. 2008;372:2152-61.
92. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorv-astatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-18. (Pubitemid 32259905)
93. Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29:1220-26. Deleted in Press. (Pubitemid 44125913)
94. Baigent C, Blackwell L, Emberson J, et al. Effcacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.
95. Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65 000 patients. J Am Coll Cardiol. 2008;52:1769-81.
96. Dale KM, White CM, Henyan NN, et al. Impact of statin dosing intensity on transaminase and creatine kinase. Am J Med. 2007;120:706-12. (Pubitemid 47189656)
97. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757-67.
98. Roberts MD. Crestor (rosuvastatin calcium) NDA 21-336 JUPITER. Paper presented at US Food and Drug Administration, Endocrinologic and Metabolic Drugs Advisory Meeting, December 15, 2009. Gaithersburg, MD: US Food and Drug Administration; 2009.
99. Clofbrate and niacin in coronary heart disease. JAMA. 1975;231:360-81.
100. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol. 2007;99:22C-31C.
101. Brown BG, Zhao XQ. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol. 2008;101:58B-62B.
102. Grundy SM, Vega GL, McGovern ME, et al. Effcacy, safety, and tolerabil-ity of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the effcacy of niaspan trial. Arch Intern Med. 2002;162:1568-76. (Pubitemid 34765005)
103. Crouse JR, 3rd. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med. 1987;83:243-48.
104. Thompson GRHEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008;198:247-55.
105. Schwertz DW, Badellino KO. High-dose statin therapy for secondary prevention of stroke: stroke prevention by aggressive reduction in cholesterol levels study review. J Cardiovasc Nurs. 2008;23:8-13.
106. Rossebo AB, Pedersen TR, Allen C, et al. Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Am J Cardiol. 2007;99:970-73. (Pubitemid 46483289)
107. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9438 patients with chronic kidney disease. Am Heart J. 2010;160:785-794. e10.
108. Yokoyama M, Origasa HJELIS Investigators. Effects of eicosapentae-noic acid on cardiovascular events in Japanese patients with hypercho-lesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). Am Heart J. 2003;146:613-20. (Pubitemid 37281704)
109. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfbrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-45. (Pubitemid 17147964)
110. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-74.
111. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351-64.
112. Rubins HB, Robins SJ, Collins D, et al. Gemfbrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-418. (Pubitemid 29362514)
113. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofbrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-61.
114. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropip-rant: trial design, pre-specifed muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279-91.
115. De Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307-16. (Pubitemid 39223221)
116. Koren MJ, Hunninghake DBALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol. 2004;44:1772-79. (Pubitemid 39424074)
117. Knopp RH, d' Emden M, Smilde JG, et al. Effcacy and safety of ator-vastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478-85. (Pubitemid 44127567)
118. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus "usual" care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18:220-28.
119. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-92. (Pubitemid 33126837)
120. Serruys PWJC, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful frst percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287:3215-22. (Pubitemid 34686102)
121. Sakamoto T, Kojima S, Ogawa H, et al. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol. 2006;97:1165-71.
122. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group; ArmitageJ, Bowman L, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a doubleblind randomised trial. Lancet. 2010;376:1658-69.
123. Ahmed S, Cannon CP, Murphy SA, et al. Acute coronary syndromes and diabetes: is intensive lipid lowering benefcial? Results of the PROVE IT-TIMI 22 trial. Eur Heart J. 2006;27:2323-29. (Pubitemid 44453576)
124. Wenger NK, Lewis SJ, Herrington DM, et al. Outcomes of using high-or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Int Med. 2007;147:1-9. (Pubitemid 351664628)
125. Chaturvedi S, Zivin J, Breazna A, et al. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology. 2009;72:688-94.
126. Shepherd J, Kastelein JJP, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: The TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008;51:1448-54. (Pubitemid 351471787)
127. Shepherd J, Kastelein J P, Bittner VA, et al. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc. 2008;83:870-79.
128. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996;335:1001-9. (Pubitemid 26338729)
129. ALLHAT Offcers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.
130. Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in 2532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care. 2005;28:1151-57. (Pubitemid 40616627)
131. Holdaas H, Fellström B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fuvastatin: the ALERT extension study. Am J Transplant. 2005;5:2929-36. (Pubitemid 43923954)
132. Cholesterol Treatment Trialists Collaboration; Kearney PM, Blackwell L, et al. Effcacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-25.
133. Messerli FH, Pinto L, Tang SSK, et al. Impact of systemic hypertension on the cardiovascular benefts of statin therapy-a meta-analysis. Am J Cardiol. 2008;101:319-25. (Pubitemid 351162960)
134. Kizer JR, Madias C, Wilner B, et al. Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. Am J Cardiol. 2010;105:1289-96.
135. Ray KK, Seshasai SRK, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65 229 participants. Arch Intern Med. 2010;170:1024-31.
136. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefts of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.
137. Bukkapatnam RN, Gabler NB, Lewis WR. Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis. Prev Cardiol. 2010;13:84-90.
138. Mizuno K, Nakaya N, Ohashi Y, et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation. 2008;117:494-502.
139. Bonovas S, Filioussi K, Tsantes A, et al. Use of statins and risk of haema-tological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies. Br J Clin Pharmacol. 2007;64:255-62. (Pubitemid 47283870)
140. Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556-64.
141. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term beneft with niacin. J Am Coll Cardiol. 1986;8:1245-55. (Pubitemid 17208898)
142. Parolari A, Tremoli E, Cavallotti L, et al. Do statins improve outcomes and delay the progression of non-rheumatic calcifc aortic stenosis? Heart. 2011;97:523-29.